Reagents News and Research

RSS

China Medical Technologies first-quarter fiscal 2010 revenues decrease 10.9% to RMB186.2 million

China Medical Technologies, Inc., a leading China-based advanced in-vitro diagnostic company, today announced its unaudited financial results for the first fiscal quarter ended June 30, 2010.

16 Aug 2010

Problems with analytical study design and data misinterpretation leads to biomarker failure: Report

The boom in cancer biomarker investments over the past 25 years has not translated into major clinical success. The reasons for biomarker failures include problems with study design and interpretation, as well as statistical deficiencies, according to an article published online August 12 in The Journal of the National Cancer Institute.

13 Aug 2010

Amorfix first-quarter fiscal 2011 net loss from operations increases to $1,724,745

Amorfix Life Sciences, a product development company focused on misfolded protein diseases, today announced its operational and financial results for the three months ended June 30, 2010.

12 Aug 2010

Swift Biosciences completes $3 million Series A financing

Swift Biosciences Inc., a Michigan-based life sciences company, today announced the recent completion of a $3 million Series A financing led by the venture firm DFJ Mercury. DFJ Mercury was joined in the Series A by several Michigan-based individual investors who also helped launch the Company with seed funding in January 2010. Daniel Watkins of DFJ Mercury will join the company's Board of Directors.

12 Aug 2010

GoTaq 2-Step RT-qPCR System allows researchers to detect target genes

The new Promega GoTaq 2-Step RT-qPCR System allows researchers to detect target genes expressed at low levels even with hard-to-amplify samples. Enhanced sensitivity of the two-step system extends the broad dynamic range of RNA quantitation and provides a robust, gene expression analysis tool.

11 Aug 2010

StemCells second-quarter net loss decreases to $4.61 million

StemCells, Inc., a leading stem cell company developing and commercializing novel stem cell therapeutics and tools for use in stem cell-based research and drug discovery, today reported financial results and business highlights for the second quarter ended June 30, 2010.

11 Aug 2010

GenMark second-quarter revenues increase 162% to $651,000

GenMark Diagnostics, Inc. today reported revenues of $651,000 for the quarter ending June 30, 2010, a 162% increase over second quarter 2009. Net loss for the second quarter was $5.1 million, or $0.60 per share, compared to a net loss of $4.3 million and $1.08 per share for the same period last year.

10 Aug 2010

Epitomics launches EP Clone Rabbit Monoclonal Antibodies

Epitomics, Inc., the rabbit monoclonal antibody company, announces today the launch of EP Clone™ Rabbit Monoclonal Antibodies and their detection systems for pathology applications. These diagnostic immunohistochemistry (IHC) products are manufactured by the In Vitro Diagnostic (IVD) Division of the Company. This new line of products are developed in compliance with regulation for IHC antibodies and detection systems in the United States, these products are manufactured under FDA's Quality System Regulation (21 CFR, Part 820).

9 Aug 2010

SeraCare optimizes ACCURUN 341 Nucleic Acid Positive controls

SeraCare Life Sciences, Inc. today announced that the Company has developed a new series of controls in its ACCURUN portfolio to monitor and validate molecular diagnostic test performance for detection of Chlamydia trachomatis and Neisseria gonorrhoeae (CT/NG). Through collaboration with instrument and reagent manufacturers, SeraCare has optimized the ACCURUN 341 Nucleic Acid Positive controls specifically for use with the three most popular assays currently on the market; the Gen-Probe APTIMA Combo 2 Assay, the Roche COBAS AMPLICOR CT/NG Test, and the Becton, Dickinson BD ProbeTec ET System.

6 Aug 2010

Alnylam second-quarter revenues increase to $26.6 million

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter ended June 30, 2010, and company highlights.

5 Aug 2010

Sigma-Aldrich, NHLBI and BU collaborate in atherosclerotic cardiovascular disease research

Sigma-Aldrich® today announced it has entered into an agreement with the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health, and Boston University (BU) to develop methods to measure several potential biomarkers of atherosclerotic cardiovascular disease (CVD) using plasma samples from the NHLBI's Framingham Heart Study (FHS), one of the most prestigious clinical studies in medicine. Funding for the project is provided by the NHLBI to Sigma-Aldrich under a research subaward agreement with BU.

5 Aug 2010

IL releases new HemosIL HIT-Ab(PF4-H) assay

Instrumentation Laboratory (IL) today announced the release of the new HemosIL HIT-Ab(PF4-H) assay as a European CE IVD Mark product under the European Directive on In Vitro Diagnostic Medical Devices. Delivering results in minutes, the HemosIL HIT-Ab(PF4-H) assay detects total immunoglobulin against Platelet Factor 4-Heparin complexes, the antibodies associated with the pathology of HIT.

4 Aug 2010

Sangon Biotech, Bio Basic complete $10 million round of funding from Qiming Ventures

Sangon Biotech, a Shanghai based life science research service company, and Bio Basic Inc. (BBI), a Toronto based life science research service company, announced today the completion of a $10 million round of funding from Qiming Ventures. The company is using the funding to scale research & development, marketing and sales of its life science research tools including biochemical reagents, protein, antibody, research kit, DNA synthesis service, etc. to meet increasing demand.

3 Aug 2010

Idaho Technology signs licensing agreement with E. I. du Pont de Nemours

Idaho Technology, Inc. has signed a licensing agreement with E. I. du Pont de Nemours and Company acting through its DuPont Qualicon Business covering reagents or methods using SYBR® Green I technology and post-PCR melting curve analysis.

31 Jul 2010

Life Technologies second-quarter Non-GAAP revenue increases 8% to $906 million

Life Technologies Corporation today announced results for its second quarter ending June 30, 2010. Non-GAAP revenue for the second quarter was $906 million, an increase of 8 percent over the $839 million reported for the second quarter of 2009. Excluding the impact of currency and prior acquisitions and divestitures, organic revenue for the quarter grew 6 percent over the same period in the previous year.

30 Jul 2010

Abaxis first-quarter revenues increase 18% to $35.0 million

ABAXIS, Inc., a medical products company manufacturing point-of-care blood analysis systems, today reported financial results for the first fiscal quarter ended June 30, 2010.

30 Jul 2010

Thermo Fisher Scientific introduces low evaporation plates for cell culture and high content analysis

Thermo Fisher Scientific Inc., the world leader in serving science, today announced the Thermo Scientific Nunc Edge 96-well Plates for cell-based assays.

From Thermo Fisher Scientific Inc. 29 Jul 2010

BD third-quarter revenues increase 3.2% to $1.878 billion

BD, a leading global medical technology company, today reported quarterly revenues of $1.878 billion for the third fiscal quarter ended June 30, 2010, representing an increase of 3.2 percent from the prior-year period, or 3.9 percent on a foreign currency-neutral basis.

From BD (Becton, Dickinson and Company) 29 Jul 2010

PFSCM wins Supply Chain Innovation Award, Best Value Supply Chain Provider Award

The Partnership for Supply Chain Management, a partner of the U.S. Agency for International Development under the U.S. President's Emergency Plan for AIDS Relief, has won two prestigious awards for groundbreaking work on PEPFAR's Supply Chain Management System. PFSCM received the Supply Chain Innovation Award and Best Value Supply Chain Provider Award during the European Supply Chain and Logistics Summit held in Prague.

29 Jul 2010

Positive results from study with Genome Sequencer FLX System for HIV drug-resistant mutation detection

454 Life Sciences, a Roche Company, has announced promising new results from a multi-site collaborative research study which used the company's Genome Sequencer FLX System to perform HIV drug-resistant mutation detection.

28 Jul 2010